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Objectives: The suitability of general HTA methodology for medical devices is gaining interest as a topic of scientific discourse. Given the broad range of medical devices, there might
be differences between groups of devices that impact both the necessity and the methods of their assessment. Our aim is to develop a taxonomy that provides researchers and policy
makers with an orientation tool on how to approach the assessment of different types of medical devices.
Methods: Several classifications for medical devices based on varying rationales for different regulatory and reporting purposes were analyzed in detail to develop a comprehensive
taxonomic model.
Results: The taxonomy is based on relevant aspects of existing classification schemes incorporating elements of risk and functionality. Its 9 × 6 matrix distinguishes between the
diagnostic or therapeutic nature of devices and considers whether the medical device is directly used by patients, constitutes part of a specific procedure, or can be used for a variety
of procedures. We considered the relevance of different device categories in regard to HTA to be considerably variable, ranging from high to low.
Conclusions: Existing medical device classifications cannot be used for HTA as they are based on different underlying logics. The developed taxonomy combines different device
classification schemes used for different purposes. It aims at providing decision makers with a tool enabling them to consider device characteristics in detail across more than one
dimension. The placement of device groups in the matrix can provide decision support on the necessity of conducting a full HTA.
Keywords: Health technology assessment, Medical devices, Classification
Health technologies such as medical devices are an essential
part of health care. The European Union defines a medical de-
vice as “[ . . . ] any instrument, apparatus, appliance, software,
material or other article, whether used alone or in combina-
tion, together with any accessories [ . . . ]” (1), which includes
a broad range of different products for purposes such as pre-
vention, diagnosis, monitoring, treatment, alleviation of dis-
ease, or compensation for an injury or handicap (1). Many
of these devices have led to important improvements in di-
agnosis and treatment of diseases such as better health out-
comes in terms of higher life expectancy and/or better quality
of life (2–4). However, their rapid pace of innovation might
also be associated with risks (5) and cause harm to patients.
Recent examples arising from the use of medical devices in-
clude recalls of specific types of breast implants (6), artifi-
cial hips (7), and implantable cardioverter-defibrillators (8).
Furthermore, fast-paced innovation is accompanied by rising
health expenditures (9;10). The combined imperatives of pa-
tient benefit and safety as well as cost containment have led
many countries to introduce regulatory instruments to identify
technologies that minimize risk and ensure value and value for
money.
There are two approaches to regulate medical technologies
depending on the point in time when regulation applies relative
to market authorization. The first approach concerns premar-
ket evaluations, which cover safety and performance aspects.
An additional demonstration of efficacy can be required de-
pending on the authorization system and the risk of the device
(e.g., high risk devices in the United States that are regulated
by the Food and Drug Administration [FDA]) (11;12). The sec-
ond approach encompasses postmarket evaluation systems that
additionally aim to consider effectiveness in the usage context,
cost-effectiveness and other domains potentially relevant for
coverage decision making, such as legal, ethical, socio-cultural,
and organizational consequences (13). Health technology as-
sessment (HTA) falls under this second approach and aims at
informing regulatory decision makers once marketing autho-
rization has been granted. It is applied to a broad range of
technologies, including pharmaceuticals, medical devices, and
public health interventions. The final intention of HTA is to pro-
vide the evidence base for decision makers, primarily at health
system level, on the consequences of adopting a given tech-
nology across the aforementioned domains (14;15). However,
most formal decision structures incorporating evidence-based
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approaches were established for pharmaceuticals (16), which
also have been the main focus of guidelines for economic eval-
uation (17). The relevance of general methodology for medical
devices, both in HTA as a whole and for economic evaluation
in particular, has been gaining interest as a topic of scientific
discourse, especially in light of new regulatory provisions for
their market authorization (18).
There are particularities characterizing medical devices,
which merit differentiated assessment practices ranging from
trial design to statistical methods to be used for the analysis of
clinical and economic data (19–21). Assessors of medical de-
vices, especially if they are provided as part of invasive and high-
risk diagnostic and therapeutic procedures frequently face the
problem of a lack of randomized controlled trials (RCTs), which
partly derives from lower evidence hurdles in market autho-
rization processes compared with pharmaceuticals (17;22;23).
McCulloch et al. (21) describe particularities and difficulties
of evaluations in the field of surgical innovations, and propose
possible solutions for the assessment of effectiveness against
current standards. They give options for alternative study de-
signs, such as parallel group nonrandomized studies or con-
trolled interrupted-time series studies, to be used when ran-
domized trials are not feasible for ethical or pragmatic reasons
(21;24).
Furthermore, given the large, heterogeneous spectrum of
devices used for diagnostic and/or therapeutic purposes, it is
safe to assume that there might be device-specific characteris-
tics that should be accounted for in HTA practice. For exam-
ple, the evaluation of diagnostic devices might be complicated
by difficulties in separating the value of the diagnosis itself
from the value of improved outcomes due to subsequent treat-
ment (17;25). Furthermore, manymedical devices are subject to
device-operator interaction, which makes the efficacy of the de-
vice contingent on the learning curve of the operator (17;22;24).
Finally, the implementation of a new device might be associ-
ated with wider organizational and economic implications for
providers, such as the need for professional trainings or new
infrastructures and associated investments (17). These partic-
ularities complicate the debate about what the related health
benefits are, where and to whom these accrue and how rational
decisions regarding coverage in relation to effectiveness and
cost can be made.
Medical devices have been classified in different ways.
While classifications facilitating market authorization aim at
categorizing medical devices according to the degree of risk
assigned to them, procurement classifications adopt a perspec-
tive relevant to pricing and reimbursement decisions. To our
knowledge, as of yet there is no detailed classification that
looks at medical devices from the viewpoint of HTA. There-
fore, the aim of this study is (i) to clarify, describe and dis-
tinguish different categories of medical devices in the context
of HTA for decision making on value and coverage and (ii) to
develop a taxonomic model that incorporates elements of exist-
ing classification schemes. With the ultimate goal of providing
researchers and policy makers with an orientation guide on how
to approach the assessment of medical devices, the taxonomy
aims at (i) highlighting the extent to which HTA is necessary
for different device categories and (ii) indicating if and how
assessment tools should be tailored to include device-specific
elements and achieve best results depending on different cat-
egories of medical devices. As a first step, the model focuses
on Europe and does not account for differences in pre- and
postmarket approval processes of medical devices beyond the
European Union (EU) context.
METHODS
The research centered on different classification schemes for
medical devices. To identify several classifications and nomen-
clatures for medical devices based on varying rationales for
different regulatory and reporting purposes, selected to account
for different characteristics of medical devices, we carried out
a search of literature. We first carried out a PubMed search
to identify relevant published literature and only considered
studies with a focus on classification and nomenclatures of
medical devices. We also reviewed legislative and policy docu-
ments in the European context discussed in the included studies.
These included the current European Union regulatory frame-
work for medical devices consisting of three directives used for
the licensing process, the international classification for medi-
cal devices used by the Global Medical Device Nomenclature
(GMDN), and the OECD Classification of Health Care Func-
tions, which considers, inter alia, reimbursement aspects. These
frameworks were analyzed in detail to inform the development
of a comprehensive taxonomic model.
RESULTS
Background on Existing Classifications of Medical Devices
Classification of Medical Devices According to EU Directives. The current Euro-
pean Union regulatory framework for medical devices con-
sists of three directives: Council Directive 93/42/EEC on med-
ical devices (MDD), Council Directive 90/385/EEC on active
implantable medical devices (AIMDD) and Council Directive
98/79/EC on in vitro diagnostic medical devices (IVDD) (26–
28). Medical device manufacturers are allowed to market their
products across all EU member states after receiving a Confor-
mite´ Europe´enne (CE) mark, which demonstrates that the safety
criteria, quality in terms of reliability, and performance are ful-
filled (11;29). However, these regulations do not require manu-
facturers to demonstrate the effectiveness or cost-effectiveness
of their products to obtain marketing authorization (30).
MDD is applicable to all medical devices that are neither
an active implantable medical device nor an in vitro diagnostic
medical device. During conformity assessment, medical de-
vices are categorized in one of four classes (I, IIa, IIb, or
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III) according to the potential risk associated with their use.
This Directive contains eighteen rules that guide categorization
based on device characteristics such as nonactive versus active
devices, noninvasive versus invasive devices and short-term use
versus long-term use of invasive devices. Different conformity
assessment procedures have to be implemented depending on
device class (26).
AIMDD is valid for active implantable medical devices,
which rely on sources such as electrical energy and are “[ . . . ]
intended to be totally or partially introduced, surgically or med-
ically, into the human body or by medical intervention into a
natural orifice, and which is intended to remain after the proce-
dure [ . . . ]”. In contrast to MDD, AIMDD contains no differen-
tiation according to identified risks associated with the device.
However, it does distinguish between custom-made products
developed specifically for an individual patient, and products
intended for clinical investigations, which include active im-
plantable medical devices used only by specialist doctors when
conducting investigations in a clinical environment. Conformity
assessment procedures are assigned according to this current
differentiation (27).
Finally, IVDD regulates the market authorization of medi-
cal devices intended for in vitro usage, such as reagents, reagent
products, calibrators, control materials, kits, instruments, ap-
paratuses, equipment, or systems, which are used alone or in
combination. Different conformity assessment procedures are
applied to groups of devices based on lists, which are annexed
to the directive. Devices are assigned to List A or List B or are
subject to specific regulations (e.g., for performance evaluation
or self-testing devices) (28).
In response to several scandals in the field of medical de-
vices in the recent past (e.g., prefilled silicone breast implants
manufactured by Poly Implants Prosthe`se [PIP] (6) and hip
implants manufactured by DePuy) (7), the European Commis-
sion issued two proposals on medical device regulation on 26
September 2012 and recommendations on the audits and as-
sessments performed by notified bodies in the field of medical
devices on 24 September 2013. The first proposal modifies both
the MDD and the AIMDD to directly categorize active im-
plantable devices into class III, where they would fall under de
facto due to their risk potential (31). The second proposal calls
for in vitro diagnostic devices to be classified into four classes
according to their risk level, which necessitates different con-
formity assessment procedures (32).
Classification of Medical Devices According to Financial Aspects. The OECD pro-
vides within its framework “System of Health Accounts” a
systematic description of financial flows concerning the con-
sumption of healthcare goods and services. The aim of the
international classification for health accounts (ICHA) is to de-
scribe healthcare systems from an expenditure perspective. One
essential dimension in this classification is that of healthcare
functions (ICHA-HC), which groups healthcare goods and ser-
vices based on their purpose. Medical devices are assigned to
different healthcare functions, for example therapeutic appli-
ances and other medical goods (HC.5.2), which include devices
such as glasses (HC.5.2.1), hearing aids (HC.5.2.2), as well
as orthotic devices and other orthopedic appliances (HC.5.2.3)
(33).
Sorenson and Kanavos (34) also developed a categoriza-
tion of medical devices according to financial aspects, taking
into account procurement policies across a sample of five Euro-
pean countries (England, France, Germany, Italy, Spain). They
explored how such practices interact with coverage and reim-
bursement approaches. They used Busse’s (35) three categories
of devices—medical aids, implantable artificial body parts, and
medical devices for the assistance of medical professionals—
to explain the relationships between actors of procurement and
purchasing interactions.
Global Medical Device Nomenclature (GMDN). The GMDNwas developed as
an international coding system formedical devices based on dif-
ferent existing nomenclatures. These included the Classification
Names for Medical Devices (CNMD) used in the United States,
the European Diagnostic Manufacturers Association (EDMA)
in vitro product classification, ISO 9999 Technical Aids for Dis-
abled Persons Classification (international use), the Japanese
Medical Device Nomenclature (JFMDA), the Norsk Klassi-
fisering Koding and Nomenklatur (NKKN), and the Universal
Medical DeviceNomenclature System (UMDNS) (36). The aim
was to provide a commonmethod for unambiguously describing
and identifying medical devices, to be used by relevant regula-
tory authorities, healthcare providers, manufacturers, suppliers,
and assessment bodies (37). Its structure is based on three levels:
device category, generic device group, and device type (37).
Developing a Taxonomic Model
Relevant elements from the identified classification schemes
were combined to form a wider taxonomic model that fol-
lows the logic of HTA for decision making on value and
coverage (Figure 1). While the GMDN seems best suited for
product identification in the context of market approval, vig-
ilance reporting and recall systems, it might be inappropri-
ate for the development of a device-taxonomy following the
logic of HTA. Thus, to systematically develop the aforemen-
tioned taxonomy, characteristics of the EU Directives and the
OECD Classification of Health Care Functions were primarily
used. Results in the form of a 9 × 6 matrix are presented in
Figure 1.
The nine rows show the categories included in the three
Directives on medical devices, which are used to determine au-
thorization processes, incorporating elements of risk and func-
tionality of device types. According to theDirective 93/42/EEC,
technologies that are neither an active implantable medical de-
vice (IV) nor an in vitro diagnostic medical device (V-VIII)
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Figure 1. Taxonomic model to classify medical devices according to their HTA relevance.
are integrated in one of four classes. While medical devices
in class I are associated with low potential risk, medium risk
is attributed to classes IIa (nonactive) and IIb (active). Class
III devices are considered high-risk while the risk associated
with active implantable devices (IV) falling under Directive
90/385/EEC is deemed particularly high. Cells numbered from
V to VIII include products classified according to the criteria
of Directive 98/79/EC on in vitro diagnostic medical devices.
Risk, if relevant to patient safety, is a dimension for HTA to be
balanced with the patient-relevant benefit. As HTA for medical
devices with high-risk potential is more important due to risks
for patients and user arising from their use, a high-risk potential
thus can also guide the selection process of devices that should
be evaluated.
The six columns of the matrix consider whether the medi-
cal device (i) is directly used by patients (A1/ A2), (ii) consti-
tutes part of a specific procedure (for which a device is deci-
sive) (B1/ B2), or (iii) can be used for a variety of procedures
(C1/ C2). This differentiation is based on procurement/ reim-
bursement activities used in the OECD Classification of Health
Care Functions (ICHA-HC) and in previous work by Busse (35)
and Perleth et al. (38). Assistive technology devices (A1/ A2)
are products dispensed to and used by patients to compensate,
maintain, or improve their functional capabilities. These include
class HC.5.2 (therapeutic appliances and medical goods) from
the OECD ICHA-HC. For HTA purposes, these technologies
are the ones closest to pharmaceuticals, at least those with a
therapeutic objective. Artificial body parts (B1/ B2) are im-
planted by medical procedures and are largely related to class
HC.1 (Curative care) in the OECD ICHA-HC. More precisely,
these technologies encompass “medical procedures” in which
the device is an important component. Medical devices for the
assistance of medical professionals (C1/ C2) include classes
HC.4.1 (Laboratory services) and HC.4.2 (Imaging services) of
the OECD ICHA-HC. A relevant issue for HTA is that these
technologies can be used in a variety of ways (by indication, by
body part, etc.). Furthermore, the columns allow for a separa-
tion of the aforementioned functions based on the diagnostic or
therapeutic use of devices.
We considered the relevance of different device categories
in regard to HTA to be considerably variable, ranging from high
to low. For taxonomic positions with low relevance, the neces-
sity of conducting an HTA in the first place should be discussed
under consideration of efficient resource use.We propose an ini-
tial, theoretical color-coding in the matrix (its plausibility will
be tested in a subsequent step, see discussion below).HighHTA-
relevance of different device categories is highlighted green, low
relevance red. Cells marked yellow include groups where rele-
vance is context-sensitive. Grey fields denote cells for which no
medical devices were identified (29 of the 54 cells). The color
coding of the taxonomy could be used to inform decision mak-
ers when an HTA should be undertaken. The extent to which
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assessment tools should be tailored to achieve best results de-
pending on different categories of medical devices is discussed
below.
DISCUSSION
The developed taxonomy combines different device classifica-
tion schemes that have been used for different purposes. Its aim
is to provide decision makers (and at a later stage, assessors)
with a tool enabling them to consider device risk in more de-
tail across more than one dimension. The placement of device
groups in the model cells provides decision support on the ne-
cessity of conducting a full HTA in the first place. It additionally
illustrates that choosing to assess a given device may be inef-
ficient in some cases (e.g., cell A1/ I) or particularly complex
in others (e.g., cell B1/ IV especially in combination with cell
B2/ IV). Furthermore, that different taxonomic positions may
merit separate additional considerations both at the conceptual
stage of assessment as well as in the methodological approach
adopted. The model can thus provide helpful insight during
the operationalization of the research question along the lines
of the PICO model and the development of the HTA protocol
(e.g., on relative taxonomic position of comparators, spectrum
of relevant outcomes, study design etc.).
The three EU Directives on medical devices used in the
licensing process focus on elements of risk and functionality.
Device risk is highly important for patient safety and is therefore
one of the required domains both in pre- and postmarket eval-
uation processes. From the HTA-perspective, it can also guide
topic prioritization processes, as policy makers should pay par-
ticular attention to high-risk devices (39) (e.g., implantable or
surgically invasive devices). Furthermore, risk classification in
the MDD also depends on the duration of patient-device con-
tact (transient: <60 min, short term: continuous use 60 min –
30 days, long term: continuous use >30 days). This might be
a significant detail to consider during assessment, as duration
of contact can play an important role in data collection (e.g.,
dental implants) and thus required duration of studies consid-
ered acceptable as evidence. Generally, longer contact duration
is associated with a higher risk for patients and, therefore, a
higher need for HTA.
The separation of assistive technology devices, artificial
body parts and devices for the assistance of medical profes-
sionals is an essential part of the matrix from an HTA view-
point. While assistive technology devices are products directly
used by patients and can in most cases be assessed “alone”,
artificial body parts and medical devices for the assistance
of medical professionals are both used within procedures and
are subject to device-operator interaction. Thus, effectiveness
outcomes are also dependent on the process or its operator.
In addition, they often need to be compared with the cur-
rent standard procedures. Therefore, assessment tools need to
be able to account for those dimensions. Furthermore, how
certain procedures are to be assessed may depend on whether
they are a part of a wider treatment plan under a physician’s
care (40).
The taxonomic model further separates diagnostic from
therapeutic devices, thus recognizing that different methodolog-
ical approaches need to be adopted depending on the nature of
the device. This is in agreement with international reference
models, such as the HTA Core ModelTM developed by EU-
netHTA. TheModel’s second versionwas published in late 2013
and comes in different iterations for diagnostic and therapeutic
technologies, the former explicitly addressing issues of clinical
utility and clinical validity of diagnostic tests (41). Furthermore,
NICE in England has a separate program for diagnostic tech-
nologies, incorporating appropriate methods (42). As a rule, it
is important to recognize that for some devices, it is challenging
to separate the value of the diagnostic test per se from the value
of improved outcomes as a result of subsequent treatment. We
argue that a potential approach for devices with both diagnostic
and therapeutic functions (cell combination B1/ IV and B2/ IV)
would be for the two components to be considered separately.
In its presented form, the matrix model is not without lim-
itations. The color-coded relevance of HTA for each device
category currently relies on several assumptions. Thus, to test
the model’s plausibility, a subsequent step in our work entails
filtering available HTA reports of European institutions and as-
signing taxonomic positions to devices assessed. Furthermore,
the approach toward risk used in the EU regulation and trans-
ferred to the technology is product-specific, thus ignoring the
contribution of patient characteristics (such as severity of con-
dition) toward the overall risk of the intervention. Finally, as
the current taxonomy is focused on the European context, it
is possible to strengthen the model by including classification
criteria from other contexts, such as those of the FDA.
Issues that pertain to individual device groups, such as bat-
tery life for active implantable devices or learning curves where
device-operator interaction applies, may pose additional chal-
lenges that need to be recognized and be accounted for to pro-
duce robust and representative assessments. Therein lies one of
the intentions of the presented model, namely to fuel the debate
on when and to what extent a differentiated approach is appro-
priate and necessary. Thus, the taxonomy does not elaborate on
individual elements at this stage but rather draws attention to
the categorical position of each device and its core properties to
point in the direction of what device-specific elements may be.
The next step in our work will include the establishment of ba-
sic methodologies per taxonomic position to explicitly consider
particularities of different categories of medical devices.
CONCLUSIONS
Existing medical device classifications are not sufficient for the
purposes ofHTAevaluation as they are based on different under-
lying logics. Furthermore, general HTA methodology, while it
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may incorporate important considerations such as the therapeu-
tic versus diagnostic nature of devices, does not consistently
account for device-specific elements such as device-operator
interaction, duration of patient-device contact, level of device
activity, or combined diagnostic/therapeutic functionality. The
new developed taxonomy combines the two worlds and add fur-
ther considerations to provide a tool enabling decision makers
to consider device risk in more detail across more than one
dimension; it can thus provide decision support on the neces-
sity of conducting a full HTA in the first place. The taxonomy
thus may be considered an important step toward advancing the
debate on HTA/economic evaluation by grouping medical de-
vices according to their relevance for HTA activities. Ongoing
steps include testing taxonomy’s plausibility by filtering avail-
able HTA reports produced by European institutions to assign
medical devices a taxonomic position, and establishing basic
methodologies (e.g., study design requirements) in HTA, which
explicitly consider peculiarities of different categories of med-
ical devices.
ACKNOWLEDGEMENTS
We are grateful to Sabine Fuchs, Britta Olberg and Susanne
Felgner for their constructive comments.
CONFLICTS OF INTEREST
This paper is the result of research that was funded through the
European Commission’s FP7 Cooperation Work Programme:
Health (Grant Agreement Number 305983; acronym AD-
VANCE HTA). The European Commission is not responsible
for the content of the paper. The authors declare no further
conflict of interest in conjunction with this work.
REFERENCES
1. European Parliament and Council of the European Union. Directive
2007/47/EC of the European Parliament and of the Council of 5
September 2007 amending Council Directive 90/385/EEC on the ap-
proximation of the laws of the Member States relating to active im-
plantable medical devices, Council Directive 93/42/EEC concerning
medical devices and Directive 98/8/EC concerning the placing of bio-
cidal products on the market. http://ec.europa.eu/consumers/sectors/
medical-devices/files/revision_docs/2007-47-en_en.pdf (accessed June
3, 2015).
2. Robinson JC. Value-based purchasing for medical devices. Health Aff
(Millwood). 2008;27:1523-1531.
3. Cutler DM. The lifetime costs and benefits of medical technology. J
Health Econ. 2007;26:1081-1100.
4. Sorenson C, Drummond M, Wilkinson G. Use of innovation payments
to encourage the adoption of new medical technologies in the English
NHS. Health Policy Technol. 2013;2:168-173.
5. Horton R. Offline: A serious regulatory failure, with urgent implications.
Lancet. 2012;379:106.
6. Heneghan C. The saga of Poly Implant Prosthe`se breast implants. BMJ.
2012;344:e306.
7. Cohen D. How safe are metal-on-metal hip implants? BMJ.
2012;344:e1410.
8. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein
LM. Recalls and safety alerts involving pacemakers and implantable
cardioverter-defibrillator generators. JAMA. 2001;286:793-799.
9. Hillman BJ. Government health policy and the diffusion of new medical
devices. Health Serv Res. 1986;21:681-711.
10. Borgonovi E, Busse R, Kanavos P. Financing medical devices in Europe:
Current trends and perspectives for research. Eurohealth. 2008;14:1-3.
11. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the
United States and the EuropeanUnion.NEngl JMed. 2012;366:848-855.
12. Kaplan AV, BaimDS, Smith JJ, et al. Medical device development: From
prototype to regulatory approval. Circulation. 2004;109:3068-3072.
13. Zentner A, Busse R. Bewertung von Arzneimitteln – Wie gehen andere
La¨nder vor? Gesundheit Ges Wiss 2011;11:25-34.
14. Draborg E, Gyrd-Hansen D, Poulsen PB, et al. International compari-
son of the definition and the practical application of health technology
assessment. Int J Technol Assess Health Care. 2005;21:89-95.
15. Migliore A, Ratti M, Cerbo M, et al. Health technology assessment:
Managing the introduction and use of medical devices in clinical practice
in Italy. Expert Rev Med Devices. 2009;6:251-257.
16. Hutton J, McGrath C, Frybourg JM, et al. Framework for describing
and classifying decision-making systems using technology assessment
to determine the reimbursement of health technologies (fourth hurdle
systems). Int J Technol Assess Health Care. 2006;22:10-18.
17. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices
and drugs - same or different? Value Health. 2009;12:402-404.
18. Campillo-Artero C. A full-fledged overhaul is needed for a risk and
value-based regulation of medical devices in Europe. Health Policy.
2013;113:38-44.
19. WHO. Development of medical device policies. WHO Medical
device technical series. 2011. http://whqlibdoc.who.int/publications/
2011/9789241501637_eng.pdf?ua=1 (accessed June 3, 2015).
20. Kirisits A, Redekop WK. The economic evaluation of medical devices.
Appl Health Econ Health Policy. 2013;11:15-26.
21. McCulloch P, Altman DG, Campbell WB, et al. No surgical in-
novation without evaluation: The IDEAL recommendations. Lancet.
2009;374:1105-1112.
22. Taylor RS, Iglesias CP. Assessing the clinical and cost-effectiveness
of medical devices and drugs: Are they that different? Value Health.
2009;4:404-406.
23. Hulstaerta F, Neyta M, Vinck I, et al. Pre-market clinical evaluations
of innovative high-risk medical devices in Europe. Int J Technol Assess
Health Care. 2012;28:278-284.
24. Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical
innovation Lancet. 2009;374:1097-1104.
25. Bossuyt PM, Irwig L, Craig J, et al. Comparative accuracy: Assessing
new tests against existing diagnostic pathways. BMJ. 2006;332;1089-
1092.
26. European Parliament and Council of the European Union. Coun-
cil Directive 93/42/EEC of 14 June 1993 concerning medi-
cal devices. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=
CELEX:31993L0042&from=EN (accessed June 3, 2015).
27. European Parliament and Council of the European Union. Coun-
cil Directive 90/385/EEC of 20 June 1990 on the approximation
of the laws of Member states relating to active implantable med-
ical devices. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=
CELEX:31990L0385&from=EN (accessed June 3, 2015).
28. European Parliament and Council of the European Union. Council
Directive 98/79/EC of 27 October 1998 on in vitro diagnostic med-
ical devices. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=
CELEX:31998L0079&from=EN (accessed June 3, 2015).
29. Altenstetter C. EU and member state medical devices regulation. Int J
Technol Assess Health Care. 2003;19:228-248.
329 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:5, 2015
https://doi.org/10.1017/S0266462315000562
Downloaded from https://www.cambridge.org/core. Universitaetsbibliothek, on 26 Oct 2017 at 13:50:34, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Henschke et al.
30. Altenstetter C. Regulating health care technologies and medical supplies
in the European Economic Area. Health Policy. 1996;35:33-52.
31. European Commission 2012. Proposal for a regulation of the Eu-
ropean parliament and of the council on medical devices, and
amending Directive 2001/83/EC, regulation (EC) No 178/2002 and
regulation (EC) No 1223/2009. http://ec.europa.eu/health/medical-
devices/files/revision_docs/proposal_2012_542_en.pdf (accessed June
3, 2015).
32. European Commission 2012. Proposal for a regulation of the Euro-
pean parliament and of the council on in vitro diagnostic medical
devices. http://ec.europa.eu/health/medical-devices/files/revision_docs/
proposal_2012_541_en.pdf (accessed June 3, 2015).
33. OECD,Eurostat,WHO.A systemofHealthAccounts.OECDPublishing.
2011. http://www.who.int/nha/sha_revision/sha_2011_final1.pdf (ac-
cessed June 3, 2015).
34. Sorenson C, Kanavos P. Medical technology procurement in Europe: A
cross-country comparison of current practice and policy. Health Policy.
2011;100:45-50.
35. Busse R. Decision-making: The link between reference pricing and
procurement. Brussels. 15.10.2008. http://www.mig.tu-berlin.de/
fileadmin/a38331600/2008.lectures/Brussel_2008.10.15_rb_EHTI.pdf
(accessed June 3, 2015).
36. Anand K, Saini SK, Singh BK, et al. Global medical device nomencla-
ture: The concept for reducing device-related medical errors. J Young
Pharm. 2010;2:403-409.
37. GMDN Agency. The global medical device nomenclature. 2012.
https://www.gmdnagency.org/ (accessed June 3, 2015).
38. Perleth M, Busse R, Schwartz FW. Regulation of health-related tech-
nologies in Germany. Health Policy. 1999;46:105-126.
39. Kru¨ger LJ, Wild C. Evidence requirements for the authoriza-
tion and reimbursement of high-risk medical devices in the
USA, Europe, Australia and Canada: An analysis of seven high-
risk medical devices. Vienna: Ludwig Boltzmann Institut fuer
Health Technology Assessment (LBIHTA); HTA-Projektbericht 73.
2013
40. Olberg B, Perleth M, Busse R. The new regulation to investigate
potentially beneficial diagnostic and therapeutic methods in Ger-
many: Up to international standard? Health Policy. 2014;117:135-
145.
41. EUnetHTA. Joint Action 2,Work Package 8. HTACoreModel R© version
2.0; 2013. http://www.corehta.info/BrowseModel.aspx (accessed June 3,
2015).
42. Adrian Newland, Chair, NICE Diagnostics Advisory Committee. NICE
diagnostics assessment programme. Ann R Coll Surg. 2011;93:412-413.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:5, 2015 330
https://doi.org/10.1017/S0266462315000562
Downloaded from https://www.cambridge.org/core. Universitaetsbibliothek, on 26 Oct 2017 at 13:50:34, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
